Website has moved, visit corporate site
Evrenzo (AstraZeneca) (evrenzo.com) scores 55 out of 100 on Brand Analyzer, placing it in the Early Stage tier among Healthcare brands, in the 3rd percentile of 10550 Healthcare brands.
Evrenzo is a pharmaceutical product developed and marketed by AstraZeneca, a global biopharmaceutical company. It is part of AstraZeneca's broader portfolio of medicines aimed at improving patient outcomes through science-driven innovation. The product's official website serves as a resource hub for healthcare professionals, patients, and caregivers, offering information, product resources, and company updates related to AstraZeneca's treatments.
| Brand Name | Evrenzo (AstraZeneca) |
|---|---|
| Domain | evrenzo.com |
| Industry | Healthcare |
| Parent Company / Owner | AstraZeneca |
| Main Competitors | Amgen (90/100), Johnson & Johnson (87/100), Pfizer (89/100), GSK (83/100), Akebia Therapeutics |
Moz Domain Authority 10/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "For more information, product resources, and company updates," (Meta description: 8 words. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on X (Twitter), Instagram, YouTube; no detected presence on LinkedIn, Facebook, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Evrenzo (AstraZeneca)?", Claude could identify the brand as of September 2026. Evrenzo is the brand name for roxadustat, an oral medication developed originally by FibroGen and marketed by AstraZeneca (and Astellas in some markets) for treating anemia associated with chronic kidney disease. It works by stabilizing hypoxia-inducible factor (HIF), which stimu Best known for Being one of the first oral HIF-PH inhibitors approved for anemia in chronic kidney disease patients, offering an alternative to injectable erythropoiesis-stimu.
When asked "Best brands similar to Evrenzo (AstraZeneca)?", Claude would recommend Evrenzo (AstraZeneca) as of September 2026. It's a genuinely notable drug in the CKD-anemia treatment space and would come up naturally if discussing alternatives to traditional ESAs like Aranesp or Epogen.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Evrenzo (AstraZeneca)'s main competitors in Healthcare: Amgen (90/100), Johnson & Johnson (87/100), Pfizer (89/100), GSK (83/100).
Sources: Brand Analyzer scan
Evrenzo (AstraZeneca) has low AI-search visibility, scoring 8/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 7, recommendation 24). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Evrenzo (AstraZeneca) official site
Evrenzo (AstraZeneca) scores 24/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Evrenzo (AstraZeneca) official site
Evrenzo (AstraZeneca) can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Evrenzo (AstraZeneca) official site
Evrenzo (AstraZeneca) scores 8/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Evrenzo (AstraZeneca) has a weak AI-visibility profile at 8/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (24/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 10/100. In a live check, Claude could already identify Evrenzo (AstraZeneca) from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Evrenzo (AstraZeneca): Eaglesoft (55/100), Design Interactive (55/100), Exscribe (55/100), Functional Pathways (55/100).
A step up - brands to learn from: Word of Mouth Technology (56/100), Werskincare (56/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.